Status and phase
Conditions
Treatments
About
To test the feasibility of theranostic targeting the PSMA receptor in STS patients by Ga-68-PSMA-11 PET/CT and Lu-177-ITG-PSMA-1 treat-ment with special emphasis on vascular disruption using a translational approach.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Platelets < 75,000/µL. Leukocytes < 2,500/µL Haemoglobin < 80 g/L. • Disturbance of liver function with: Total bilirubin > 2 times the upper limit of the norm ASAT/ALAT > 3 times the upper limit without the presence of liver metastases ASAT/ALAT > 5 times the upper limit in the presence of liver metastases
• Hypersensitivity to any of the ingredients of the injectable product
Primary purpose
Allocation
Interventional model
Masking
14 participants in 1 patient group
Loading...
Central trial contact
John O Prior, PhD MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal